関連する実験動画
Updated: Sep 10, 2025
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.1K
キスペプチンは,代謝機能障害に関連したステアトス性肝疾患における肝臓のデノボリポゲネシスを軽減する
Kimberly Izarraras1, Ankit Shah1, Kavita Prasad1
1Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA.
Cells
|August 27, 2025
まとめ
キスペプチンの治療は,デノボ脂質生成 (DNL) を減らし,代謝機能障害に関連した脂肪性肝疾患 (MASLD) に対する保護を提供します. この発見はキスペプチンを強調する
科学分野:
- 代謝疾患の研究
- ホルモンシグナル伝達経路
- ヘパトロジー
背景:
- メタボリック機能障害に関連した脂肪性肝疾患 (MASLD) は,デノボリポゲネシス (DNL) の増加と関連しています.
- KISS1R経由のキスペプチンのシグナル伝達は,肝臓ステアトーシスとMASLDから保護することが知られている.
- MASLDにおけるDNLに対するキスペプチンの直接的な影響は,まだ完全に解明されていない.
研究 の 目的:
- MASLDのマウスモデルでキスペプチンの治療がデノボリポゲネシス (DNL) を直接抑制するかどうかを調査する.
- キスペプチンが肝臓の脂質代謝とDNLに影響を与える分子メカニズムを探求する.
主な方法:
- キスペプチンを投与したマウスモデル (ダイアモンドマウス) を用いた.
- DNLの代謝追跡のために2H2O濃縮水と質量スペクトロメトリーを使用した.
- 肝臓と原発性肝細胞におけるトランスクリプトミックプロファイリング,遺伝子およびタンパク質発現分析を実施した.
主要な成果:
- キスペプチンの治療は,脂肪酸性肝臓における自由脂肪酸のデノボ脂質生成 (DNL) を有意に低下させた.
- トランスクリプトミア分析により,脂肪酸の代謝が低下し,脂質滴の調節剤であるCIDEAの低下が示された.
- キスペプチンの投与は,DNLの重要な調節体であるSREBP- 1cとCIDEAタンパク質のレベルを低下させた.
結論:
- キスペプチンが刺激した強化されたKISS1R信号は,肝臓のDNLを効果的に制限します.
- キスペプチンの治療は,DNL経路をターゲットにすることで,MASLDの進行を制限する上で重要な役割を果たしています.
関連する概念動画
01:24Overview of Lipid Metabolism
2.4K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.4K
01:58Cell Specific Gene Expression
13.9K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.9K
01:25Lipid Catabolism
165
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
165
01:06Lipid Digestion
93.8K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
93.8K
01:30Liver Physiology
1.2K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
1.2K
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416